BRNS — Barinthus Biotherapeutics plc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1828185 ·
Last close
$0.56
Market Cap
$22.79M
52W High
$0.76
52W Low
$0.54
ADV30
36,437
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,926,000 | -5,531,000 | 92,143,000 | 65,858,000 | 25,665,000 |
| Dec 2025 | 0 | — | -11,449,000 | -11,090,000 | 98,169,000 | 70,456,000 | 23,877,000 |
| Sep 2025 | 0 | — | -10,159,000 | -14,566,000 | 109,201,000 | 74,272,000 | 24,640,000 |
| Jun 2025 | 0 | — | -21,982,000 | -21,124,000 | 129,561,000 | 86,259,000 | 27,080,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,443,000
Investing CF
$476,000
Financing CF
$0
CapEx
$-429,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-309,628,000
Inventory
—
Receivables
$1,398,000
ST Investments
—
EBIT TTM
$-52,452,000
Pretax Income TTM
$-52,503,000
Interest Exp TTM
$51,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -63,888,000 | -66,428,000 | 98,169,000 | 23,877,000 | — | -47,979,000 |
| Dec 2024 | 14,969,000 | -51,778,000 | -61,074,000 | 160,327,000 | 30,192,000 | — | -28,940,000 |
| Dec 2023 | 802,000 | -80,453,000 | -73,347,000 | 214,506,000 | 27,511,000 | — | -50,925,000 |
| Dec 2022 | 44,703,000 | -2,801,000 | 5,342,000 | 270,205,000 | 27,004,000 | — | -14,431,000 |
TTM Snapshot
Revenues TTM
$14,969,000
NetIncome TTM
$-22,186,000
OpCashFlow TTM
$0
Assets (Latest)
$160,327,000
Forward EPS
$-1.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MDNAF | Medicenna Therapeutics Corp. | $23.08M | $0.25 | — |
| TXMD | TherapeuticsMD, Inc. | $23.50M | $2.03 | — |
| CRVO | CervoMed Inc. | $23.89M | $2.58 | — |
| AYTU | AYTU BIOPHARMA, INC | $23.94M | $2.23 | — |
| LGVN | Longeveron Inc. | $21.16M | $0.70 | — |
News headlines (Yahoo Finance, 1h cache)
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
2026-04-30 11:30 · Yahoo
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
2026-03-13 12:00 · Yahoo
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?
2025-12-15 17:00 · Yahoo
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
2025-12-10 13:00 · Yahoo
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
2025-11-07 12:30 · Yahoo
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
2025-10-24 15:00 · Yahoo
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
2025-09-30 13:56 · Yahoo
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
2025-08-07 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.